Meta-analysis Of Efficacy And Safety Of Brentuximab Vedotin In Bridging Therapy Before Stem Cell Transplantation For RRHL

OBJECTIVE: Through Meta analysis,the efficacy and safety data of Brentuximab vedotin(Bv)in bridging therapy of relapsed and refractory Hodgkin’s lymphoma(RRHL)with hematopoietic stem cell transplantation(HSCT)were obtained,providing data support for clinical RRHL drug treatment.METHODS: Eight databases were fully searched,all literatures that met the inclusion and exclusion criteria were screened,and the effect size of Bv in bridging therapy before stem cell transplantation for relapsed and refractory Hodgkin lymphoma was combined.RESULTS:A total of 18 non-randomized controlled trials were included,and the ORR and CRR were 81%(95% CI: 0.73,0.88)and 55%(95% CI: 0.41,0.68),respectively,after Bv was used for bridging therapy in patients with RRHL before stem cell transplantation.A subgroup analysis of different regimens when Bv bridged HSCT found that the ORR of Bv and bendamustine(Bv B)regimen combined with bridging therapy was 85%(95% CI: 0.75,0.93).After Bv bridging therapy and stem cell transplantation,the CRR was 61%(95%CI: 0.40,0.81),and the 2-year PFS and 2-year OS were 77%(95%CI: 0.71,0.82)and 91%(95%CI: 0.86,0.96),respectively.Grade≥3 major hematological adverse reactions were neutropenia(25%),thrombocytopenia(40%),and febrile neutropenia(11%);grade ≥3 major non-hematological adverse reactions adverse reactions included peripheral sensory nerve damage(12%),gastrointestinal reactions(5%),and infusion-related reactions(10%).CONCLUSIONS: The results of this meta-analysis suggest that in RRHL,Bvbridging HSCT therapy is effective and prolongs overall survival and progression-free survival in patients with RRHL.Among them,the Bv B combination regimen has more significant bridging treatment effect,and the adverse reactions occurred within the controllable range.